Trial Profile
The efficacy of fosaprepitant to the moderate emetic risk intravenous chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 May 2013
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Dexamethasone; Serotonin 3 receptor antagonists
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 13 Dec 2012 New trial record